Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4

Abstract

The present invention relates to a compound of formula (I) wherein Rrepresents a (C-C)alkyl group, a spiro(C-C)bicyclic ring, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherein L is either a single bond or a (C-C)alkanediyl group, and R′ represents a (C-C)cycloalkyl group, abridged (C-C)cycloalkyl group, a (C-C)heterocycloalkyl group, or a (C-C)heteroaryl group, or a R′-L- group wherein L is a (C-C)alkanediyl group, and R′ is an optionally substituted phenyl group, and wherein Rrepresents a hydrogen atom or a (C-C)alkyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits associated with Down syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan-McDermid syndrome; autism; type 1 and type 2 diabetes; abnormal folate and methionine metabolism; osteoarthritis; Duchenne muscular dystrophy; several cancers; neuroinflammation, anemia and viral and unicellular infections and for regulating body temperature.